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Hypertension is a common disease in Africa. A recent study found a 
prevalence of over 40% throughout the continent.[1] In South Africa 
(SA), the current prevalence is estimated to be 30.4%.[2] Calcium 
channel blockers (CCBs) have a prominent role in the management 
of hypertension in SA, and are recommended as first-line agents 
in black Africans, the elderly, pregnant women, and patients with 
comorbid diseases such as angina pectoris, peripheral vascular 
disease and carotid atherosclerosis.[2-6]
Drug overdose (OD), whether due to deliberate self-harm or 
accidental ingestion, is a common patient presentation encountered 
in the emergency department (ED).[7,8] Medicine-related poisonings 
predominate and are often severe, requiring emergency care.[7-10] 
Medications typically reported are those that are easily accessible or 
are prescribed by healthcare professionals, with prescription drugs 
identified as being of particular concern in deliberate self-harm.[7] 
Many of these prescription drugs form part of the essential drugs list, 
such as CCBs.
Owing to the widespread use of CCBs and a high likelihood of their 
being available in SA homes, the risk of OD exists. CCBs are highly 
lethal in severe OD if it is not treated promptly and aggressively.[11] 
Indeed, CCB ODs are responsible for more fatalities than any other 
cardiovascular agents in the USA, with an estimated 35% mortality 
rate.[12] As there is a lack of local literature in SA, we highlight the 
general principles of management, complications and problems that 
may be encountered during treatment. Recommendations are based 
on available international evidence and current best practice to assist 
in the emergency management of such cases.
Pharmacology
CCBs are divided into two main classes, the dihydropyridines (e.g. 
amlodipine and nifedipine) and the non-dihydropyridines (e.g. 
verapamil and diltiazem).[11] CCBs directly antagonise the voltage-
gated L-type calcium channels, which are found in peripheral 
vascular smooth muscle, cardiomyocytes and the pacemaker 
cells that form the cardiac conducting system.[11,13,14] Outside the 
cardiovascular system, voltage-gated L-type calcium channels are 
found in the beta cells of the pancreas, central nervous system and 
skeletal muscle.[11,13,14]
Non-dihydropyridine CCBs are used primarily to treat angina 
or cardiac arrhythmias.[11,13] They are lipophilic and have a higher 
affinity for cardiomyocytes than the dihydropyridine agents, where 
they reduce the influx of calcium during phase two of the action 
potential.[13-16] Because calcium is not able to enter the cell, excitation 
coupling in these cells cannot occur, resulting in reduced myocardial 
contractility.[15,16] Reduced binding of calcium to the calcium 
channels in the conducting system leads to slowing of sinoatrial and 
atrioventricular conduction, resulting in bradycardia.[15,16]
The dihydropyridines preferentially affect vascular smooth 
muscle in the periphery at therapeutic dosages, thereby decreasing 
peripheral vascular resistance and reducing afterload and lowering 
blood pressure (BP).[11,13] They are therefore excellent agents for the 
management of hypertension.
Toxicokinetics
Amlodipine and other slow-release CCBs are absorbed from the 
gastrointestinal tract slowly, with peak serum concentrations being 
reached within 6 - 12 hours.[11] In OD, peak concentrations may 
only be reached at 24 hours.[11,17] It is therefore important to note 
that patients may appear asymptomatic at the time of presentation, 
especially when slow-release CCBs are ingested, and then deteriorate 
24 hours later.[11] CCBs are primarily metabolised by the cytochrome 
P450 system.[17] They are highly protein bound and have a high volume 
of distribution, so are not amenable to removal by haemodialysis.[15,17]
Toxicodynamics and pathophysiology
In OD, non-dihydropyridines cause sinus bradycardia, atrio-
ventricular blocks, hypotension and cardiogenic shock.[11,15,17-19] In 
dihydropyridine OD, profound peripheral vasodilation produces 
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vasoplegic (distributive) shock.[11,15,17-20] A reflex tachycardia fails 
to occur at toxic doses, as dihydropyridines lose their preferential 
selectivity for peripheral smooth muscle and instead cause 
bradycardia and cardiogenic shock.[11,17-20] Dysrhythmias such as 
atrioventricular blocks may also therefore be seen in dihydropyri dine 
OD.[17,20] The hallmark of CCB OD is therefore circulatory shock due 
to bradycardia, poor cardiac contractility and profound peripheral 
vasodilatation.
In addition, CCBs in OD appear to exert toxic effects on L-type 
calcium channels in the beta cells of the pancreas, preventing insulin 
release. This results in hypoinsulinaemia and insulin resistance, 
causing hyperglycaemia and ketoacidosis.[11,15,17,18] In the unstressed 
state, cardiomyocytes utilise free fatty acids as the primary energy 
substrate.[17,18] In the stressed state, cardiomyocytes switch to glucose. 
It is theorised that the hypoinsulinaemic state induced by CCBs 
prevents glucose uptake into the cardiomyocytes, starving them of 
their energy substrate, further impairing cardiac contractility.[17,18]
The systemic effects of CCB-induced cardiogenic and distributive 
shock are myriad. Hypoperfusion of the brain from hypotension 
may cause impairment in consciousness. Occasionally, seizures may 
occur.[11,17,19] Lactic acidosis develops from the poor perfusion to 
end organs, as well as reduced conversion of lactate to pyruvate in 
mitochondria due to reduced entry of calcium into cells.[11,17,18] Acute 
kidney injury occurs as a result of prolonged hypoperfusion and end-
organ ischaemia.[15] Non-cardiogenic pulmonary oedema may occur 
secondary to pulmonary vasodilation and alveolar extravasation 
of fluid.[11,15,20] In addition, excessive fluid resuscitation may also 
contribute to its development.[11,13,17,20]
Management of a CCB OD
General management, resuscitation and 
decontamination
Advice from a poisons information centre should be sought if medical 
staff are unfamiliar with the management of CCB OD.[11,14,18,20] 
The Western Cape Poison Information Centre helpline is available 
24 hours a day.[21] General resuscitation measures should be started 
without delay, which include supplemental oxygen, establishment of 
reliable intravenous access and basic haemodynamic monitoring in 
the form of heart rate, BP and oxygen saturation.[11,22] This should be 
done in a closely monitored area, such as the resuscitation area of the 
ED.[14,18,22] Endotracheal intubation and ventilation may be necessary 
in severe poisonings where coma and cardiorespiratory failure 
occur.[11,13] Non-cardiogenic pulmonary oedema can occur in severe 
poisonings, requiring ventilatory support.[11,13,17] Close monitoring 
should be continued in the ED until the patient has been transferred 
to an intensive care unit (ICU) or high-care setting, as a patient may 
deteriorate precipitously.[11,17,22]
If a potentially life-threatening OD of a sustained-release CCB 
has occurred and the patient has presented within 2 hours of 
ingestion, activated charcoal 1 g/kg may be given orally to reduce 
systemic absorption of the CCB.[14,17,22] Activated charcoal should 
only be given in fully awake patients who can protect their airway 
or via a nasogastric tube after the patient has been intubated with an 
endotracheal tube.[14,17,18,22]
The time of ingestion and the number of tablets ingested should 
be sought. A potentially life-threatening OD varies depending on 
the type of CCB ingested. The exact toxic dose for each has not 
been fully established. However, it is recommended that patients 
are monitored for toxicity if >0.3 mg/kg of amlodipine is ingested 
in children,[23] and if >10 mg is ingested by an adult. Asymptomatic 
patients should be observed for 24 hours in a monitored setting if 
a sustained-release preparation has been ingested.[11,14,22] Further 
history taking should include whether concomitant ingestion with 
other medications, poisons, alcohol or illicit drugs has occurred. Beta-
blocker co-ingestion is common and requires similar management to 
CCB OD, as described below.[24]
CCB toxicity may already be evident on examination on initial 
presentation. BP may be normal or low with bradycardia.[11,17] Signs 
of distributive shock may be present, such as bounding pulses and 
warm peripheries, particularly in dihydropyridine OD.[11,14,17,19] These 
clinical signs should not be mistaken for adequate perfusion. The 
patient may have bounding pulses from peripheral vasodilation, so 
the severity of shock may be underestimated and unrecognised until 
decompensation occurs, whereupon the patient’s haemodynamics may 
deteriorate rapidly.[18] Pulmonary oedema may already be present on 
initial presentation if presentation to hospital was delayed.[13]
Bedside investigations include a 12-lead electrocardiogram (ECG) 
to look for arrhythmias.[11,17,22] Venous blood gas analysis is helpful to 
confirm the presence of metabolic acidosis and lactic acidosis,[11,17,18] 
as well as to check the baseline serum potassium.[25] Females of 
reproductive age should have a urine pregnancy test.[26] Pregnant 
patients may require specific treatment, such as being nursed in a left-
lateral position to reduce the effects of supine hypotension syndrome 
caused by compression of the inferior vena cava by the uterus, which 
may further exacerbate the shock induced by CCB OD.[26]
A serum paracetamol measurement should be done if concomitant 
medications ingested are not known, as paracetamol is the most 
common medication used in OD in SA, lacks a clinically detectable 
toxidrome, and requires specific life-saving management.[27] Other 
serum drug levels should be guided by clinical suspicion.[28]
Specific management in the symptomatic CCB OD
Two intravenous lines should be established promptly, and 20 mL/
kg crystalloid can be given initially if shock is present.[14,15,17,19,22,24] 
Avoid further excessive intravenous fluid administration, as this 
is associated with an increased risk of pulmonary oedema.[11,15,20] 
Central venous access is extremely useful, as all but mild poisonings 
will require multiple infusions to run simultaneously, and frequent 
blood gas monitoring is required.[25] Access should be obtained as 
soon as feasible.
Thirty to sixty millilitres of 10% calcium gluconate or 10 - 20 mL 
10% calcium chloride may be given intravenously over 10 - 20 minutes, 
although clinical evidence of improvement is limited. [11,14,15,17-19,22,24] 
Atropine in 0.5 - 1 mg boluses intravenously, up to a maximum of 
3 mg, may be tried for CCB-induced bradycardia. [14] Glucagon has no 
proven role in CCB OD, although it may be of benefit in beta-blocker 
ODs if sufficient quantities can be sourced.[11,14,18,24]
Patients with signs of shock such as mean arterial pressure (MAP) 
<65 mmHg or lactic acidosis despite initial fluid resuscitation should 
be started on an adrenergic agent.[12,14,15,17-19,22,24] In the SA setting, 
adrenaline is most commonly available. Adrenaline has positive 
inotropic and chronotropic effects as well as vasopressor effects in 
higher doses.[14,17] The dosage range for infusion is between 0.05 
and 1 µg/kg/min, aiming for improvement in haemodynamics and 
perfusion.[14] A good starting point for a hypotensive patient with 
CCB OD is 0.5 µg/kg/min, which can be up- or down-titrated to 
effect. Dopamine is generally not recommended.[22] In severely 
shocked patients with CCB poisoning, adrenergic agents such as 
adrenaline may not reverse shock adequately.[14,17,19,29-31]
High-dose insulin euglycaemic therapy
If the patient is not demonstrating haemodynamic improvement with 
adrenaline, high-dose insulin euglycaemic therapy (HIET) should be 
initiated while the vasopressor infusion is continued.[13,14,17,22] There is 
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no evidence to recommend a specific timeframe, although initiating 
HIET 15 minutes after the vasopressor infusion has shown no 
improvement may be reasonable. Delayed HIET has been associated 
with increased mortality.[17,18,24,30]
There are no randomised controlled studies in humans comparing 
adrenergic agents with HIET, but animal studies and case studies 
in humans consistently show HIET to be superior to adrenergic 
agents in terms of haemodynamic effects in severe CCB OD and 
shock. [14,17,18,24,25,29-32] HIET has been shown to restore haemo-
dynamic stability where high doses of multiple vasopressors have 
failed. [11,14,15,18,19,29,30] In multiple case studies it has been demonstrated 
that when HIET was initiated in CCB-induced shock, it was possible 
to wean patients off the high-dose vasopressors they had previously 
required.[13-15,18,19,31] For this reason, HIET is increasingly being 
advocated for consideration as first-line therapy,[18,19,25,30,31] although 
further evidence is required to make this standard practice.
The effect of HIET is usually seen 1 hour after initiation,[11,14,17,18,24] 
so adrenaline should be continued until the patient’s haemodynamics 
have normalised. HIET should not be delayed until ICU admission, 
as delayed HIET has been associated with increased mortality, as 
mentioned above.[17,18,24,30]
The mechanism for the efficacy of HIET, also known as high-
dose insulin therapy, is not fully understood. Its efficacy may be 
explained in three ways. Firstly, insulin acts as a catecholamine-
independent inotrope directly on cardiomyocytes.[17,25,31] Secondly, 
insulin enables the uptake of glucose into cardiomyocytes, which 
is the heart’s preferred energy substrate during stress.[17,18,25,30,31] 
Since CCBs in OD produce a hypoinsulinaemic state, glucose 
uptake into the cardiomyocytes cannot occur, impairing cardiac 
contractility. Exogenous high-dose insulin and supplemental glucose 
therefore enable uptake of glucose and therefore improve myocardial 
contractility.[17,18] Finally, insulin acts as a peripheral vasodilator 
reducing afterload, which improves systemic perfusion.[30,31] In the 
coronary arteries, this vasodilatory effect improves perfusion and 
oxygen delivery to the heart, improving inotropy.[25,30,31]
HIET is commenced with a loading dose of 1 IU/kg short-acting 
insulin intravenously[11,14,17,22,24,25,30,31] (see ‘Practical tips’ box). An 
infusion of insulin is commenced simultaneously, ranging from 1 IU/
kg/h to 10 IU/kg/h, aiming for haemodynamic stability.[17,22,25] The 
rate of HIET should be increased up to the maximum dose if shock 
persists.[11,14,17,18,22,24] In case reports, rates of up to 22 IU/kg/h have 
been used safely and effectively.[14,24] Target haemodynamic parameters 
include MAP >65 mmHg,[30] systolic BP >90 mmHg and urine output 
1 - 2 mL/kg in adults.[18,25] Higher MAPs and systolic BPs may be 
considered in patients known to have poorly controlled hypertension.
At the same time as the loading dose of short-acting insulin, 
a loading dose of 1 mL/kg of 50% dextrose water is given.[14,17,22] 
A 10% dextrose infusion should be commenced to maintain 
normoglycaemia, and fingerprick glucose testing should be done 
30 minutes after HIET is started and hourly thereafter.[11,14,17,23] 
Higher concentrations of dextrose water, for example 50%, may be 
required.[25] However, hyperglycaemia despite high doses of HIET can 
occur[24,25] and may indicate the severity of CCB poisoning.[17]
Intravenous potassium replacement should also be commenced 
once the serum potassium level is <3.5 mmol/L, similar to the 
management of diabetic ketoacidosis.[11,14,24,25] A recommended 
infusion rate for potassium can be found in the accompanying HIET 
protocol (see box).
The rationale for HIET should be thoroughly explained to medical 
and nursing staff looking after the patient, as the high doses required 
may be assumed to be a drug error and stopped, leading to worsened 
haemodynamic instability and death.[18,25,31]
Patients require intensive care or high-care admission owing 
to the intensive monitoring and multiple infusions they may 
require. [11,18,22] Transfer to an ICU may occur provided that the patient 
is haemodynamically stable enough to tolerate transport out of the 
ED. Transfer to another hospital capable of providing ICU facilities 
may be required if the patient initially presents to a facility lacking 
these resources.
Complications during treatment
Hypokalaemia and hypoglycaemia are two expected complications 
of HIET and must be monitored for and treated diligently.[11,14,17,22-25] 
Hypokalaemia and hypoglycaemia are not indications to stop HIET 
if haemodynamic stability has not yet been achieved. Hypokalaemia 
is common and seldom life threatening provided that potassium 
replacement is continued during HIET and serial serum potassium 
monitoring is done.[14,18,24] Venous blood gas monitoring is done at 
Practical tips for managing calcium channel blocker overdose
Western Cape Poison Information Centre 24-hour helpline: 0861-555-777 or (021) 938-4497
Recommended high-dose insulin euglycaemic therapy protocol
1. Loading dose of 50% dextrose 1 mL/kg intravenously.
2. Loading dose of short-acting insulin 1 IU/kg intravenously.
3. Mix insulin infusion: Withdraw 20 mL from 200 mL 0.9% saline bag. Insert 2 000 IU of short-acting insulin into the bag. Concentration 
is 10 IU/mL. Start infusion at 1 IU/kg/h.
4. Commence 10% dextrose water infusion to maintain normoglycaemia. This may be changed to a 50% dextrose infusion if required. The 
rate of dextrose is titrated based on hourly fingerstick glucose measurements. Administer 1 mL/kg 50% dextrose if blood glucose <3 
mmol/L.
5. Check fingerstick glucose 30 minutes after infusion is commenced. Continue to check hourly thereafter.
6. Do venous blood gas analysis on arrival and then 4 - 6-hourly.
7. Start potassium chloride infusion if serum potassium is <3.5 mmol/L, aiming for a serum potassium level of 2.8 - 4.5 mmol/L. 
Recommended rate 10 mmol/h, maximum rate 20 mmol/h.[34] Potassium infusions should run through a central line to avoid phlebitis 
and patient discomfort.
8. Serum magnesium should be checked and replaced if low.
9. Increase insulin infusion up to 10 IU/kg/h until haemodynamic stability is achieved, i.e. mean arterial pressure >60 mmHg, heart rate 
>60 bpm, normal sinus rhythm on electrocardiogram, urine output 1 mL/kg/h, lactate <2 mmol/L.
Consider transfer to a higher level of care if monitoring in a high-care setting and multiple infusions cannot be safely performed.
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least 4 - 6-hourly during the first 24 - 48 hours of therapy.[18,25,30] 
Supplemental potassium infusions should be stopped once the 
patient has been weaned off the HIET, because the patient is not 
inherently potassium deficient.[14,18]
It is also essential to monitor for hypoglycaemia during the course 
of treatment.[18,25,30] Supplemental 50% dextrose water boluses may 
be given additionally to maintain normoglycaemia.[14,18,24,25] The 
importance of strict glucose monitoring should be emphasised to 
medical staff, particularly in intubated patients, to avoid unrecognised 
neuroglycopenia.
There is limited consensus in the literature as to when HIET can be 
stopped, although early or abrupt withdrawal of HIET is associated 
with rebound of CCB toxicity.[18,24,25] HIET should not be stopped 
until haemodynamic stability is achieved and the patient no longer 
requires inotropic support with adrenaline. HIET should be weaned 
slowly, and this may be days after initiation.[24,25] The end-points of 
HIET therapy include maintenance of MAP >65 mmHg, heart rate 
>60 bpm, urine output 1 - 2 mL/kg, eradication of lactic acidosis, 
and improvement in the level of consciousness.[18,25,30,33] Psychological 
support and psychiatric evaluation are indicated in cases of deliberate 
self-harm once the patient has been fully treated and stabilised.
The patient in refractory shock and the patient  
in cardiac arrest
Effective cardiopulmonary resuscitation and attention to advanced 
cardiac life support principles remain the mainstay of therapy in 
CCB-induced cardiac arrest.[14,23] In refractory shock, ensure that 
the maximum doses of HIET, up to 10 IU/kg/h, have been used; 
however, even higher doses have been used safely.[18,22,24] Intravenous 
lipid emulsion therapy (ILE) may be tried in the peri-arrest or 
arrested patient, although evidence of efficacy is scarce.[14,22,24] ILE 
binds to lipophilic drugs, reducing their free concentration in target 
organs. [11] A loading dose of 1.5 mL/kg of 20% lipid emulsion is given, 
followed by an infusion of 0.25 mL/kg/m over 30 - 60 minutes. [14] 
Lipid emulsion may be found in theatre, where it is used in cases 
of local anaesthetic-induced cardiotoxicity. Finally, venoarterial 
extracorporeal membrane oxygenation is a last resort for patients in 
refractory shock where this resource is available.[11,14,24]
Conclusions
CCBs are commonly used in SA in the management of hypertension 
and other cardiovascular disease. It is essential that medical 
practitioners know how to recognise and manage CCB OD, as severe 
CCB OD is often fatal. The Poison Information Centre in Cape 
Town has a 24-hour helpline to assist practitioners with toxicology 
management. Haemodynamic monitoring and general resuscitation 
measures should be instituted without delay in patients who are 
symptomatic. Asymptomatic patients should be monitored closely for 
at least 24 hours, particularly if a slow-release CCB has been ingested. 
Intravenous fluid, calcium and vasopressors form part of the initial 
management of CCB-induced shock. HIET should be started in 
shocked patients who do not rapidly respond to initial therapy. HIET 
can be safely used in a monitored, high-care setting. Medical staff 
should be educated about the rationale of the high doses used to 
avoid premature stopping of therapy and its adverse consequences.
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